Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Beyfortus made almost $600 million in its first full year on the market in 2023, even though it was held back by manufacturing capacity constraints, and AZ and Sanofi are predicting it will cross ...

which could be a challenger to Sanofi and AstraZeneca's fast-growing Beyfortus. Clesrovimab (MK-1654) met its primary safety and efficacy endpoints in the study, including reducing medically ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Aug 17, 2024 18:48 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus ...

Pregnant mums and newborns will receive free vaccinations against respiratory syncytial virus (RSV) under the federal ...

Total income for the quarter... Aug 08, 2024 18:49 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Houman Ashrafian, MD, PhD Executive Vice President, Head of Research and Development, Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite ...

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with flagship products like Doliprane and Allegra, has been a reliable ...

Sanofi India Limited (Previously known as Aventis Pharma Limited) was incorporated in May 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 2012. The ...